RE:RE:RE:RE:RE:RE:RE:RE:Just a retrospection / Phase II mooch, RTF or not by end of Aug, if not then either regular or priority (TST notified within 14 days including deficiency, adcom date (i expect late Nov), etc)..with CCI onboard i don't expect an RTF so i will now hold through that...IMO TST will increase in price through adcom and i expect urologists to be supportive (unmet need perspective) but FDA biostats folks to go after TST and skinny data (are results proof of chance or therapy working) and if Pazdur shows up run for the hills...if webcast i may even hold during the sessions...after adcom who knows whether MCNA gets approved, OTOH you have skinny data (single arm, only 1 small P3 trial with no confirmatory trial) vs. unmet need and some reasonable long duration impact (which somewhat counteracts the "chance" dilema)...irrespective in the near term IMO CCI, etc. will be buying TST continuously to some prescribed point in time...rather interestingly and why i am investigating CCI is that one of their companies got priority and sold the voucher to ??? for $245M US (now that is intriguing)...
..what else do you want to know??
..re. ONC worst led biotech i know of the CEO is truly incompetent and very destructive to shareholders..IMO on any real chance of success he will take ONC private..FYI i have bought and sold ONC for over a decade..the CEO (who actually works securities laws with great expertise) predicted Reo would be approved in 2003 (can you say pump and dump)?? but while CEO destroyed the shareprice proactively via ATM (in front of coming delisting from NAS) it may be a good trade for the next few months (he raised $30M while cratering price and thus guarenteeing his employment for the next 10 years (which IMO is his primary objective)...
...regards... TST is IMO a very good investment for the next few months